GoldenGolden
Advanced Search
Relay Therapeutics (company)

Relay Therapeutics (company)

Relay Therapeutics is a Cambridge, Massachusetts-based developer of an allosteric drug-discover platform that is intended to apply computational techniques to protein motion.

Relay Therapeutics is a precision oncology company that uses protein motion to develop cancer therapeutics. It was founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson. Relay Therapeutics started its initial public offering (IPO) on July 20th, 2020. Prior to that, the company raised funding until its Series C round, receiving financing from investors such as SoftBank, Foresite Capital, and Tavistock Group. Relay Therapeutics is headquartered in Cambridge, Massachusetts, United States.

Product and Service

Relay Therapeutics has its own proprietary drug development platform called Dynamo, which integrates long-timescale molecular dynamics simulations and machine learning together with room-temperature crystallography and cryoEM. Dynamo also utilizes an approach that Relay Therapeutics called as motion-based drug design (MBDD), which is a form of drug discovery process that allows for long-timescale simulations of protein dynamics. Through these techniques and existing genome data, Relay Therapeutics is able to develop compounds that target specific genes, with recently developed drugs aimed at SHP-2, FGFR2, and PI3Kα.

Timeline

May 3, 2021
Relay Therapeutics, Inc. announces the appointments of Tara O'Meara as senior vice president of clinical development operations, and Charles Ferté as vice president, global medical lead for RLY-4008.
December 2018
Relay Therapeutics raises a $400,000,000 series C round from Biotechnology Value Fund, Casdin Capital, D. E. Shaw Research, EcoR1 Capital, Foresite Capital, GV, Perceptive Advisors, SoftBank Vision Fund and Tavistock Group.
December 2017
Relay Therapeutics raises a $63,000,000 series B round from Alexandria Venture Investments, Biotechnology Value Fund, Casdin Capital, EcoR1 Capital, GV, Section 32 and Third Rock Ventures.
September 2016
Relay Therapeutics raises a $57,000,000 series A round from Third Rock Ventures.
2015
Relay Therapeutics was founded by David E. Shaw, Dorothee Kern, Mark Murcko and Matthew Jacobson.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 20, 2021
BioSpace
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.
Alex Keown
May 14, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
BioSpace
May 10, 2021
BioSpace
Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, announced the appointment of Patrick Riley, Ph.D., as senior vice president of artificial intelligence.
Brandon May
May 3, 2021
BioSpace
Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O'Meara and Charles Ferté.
Brandon May
May 3, 2021
BioSpace
Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O'Meara and Charles Ferté.
Ben Adams
May 3, 2021
FierceBiotech
Last month we found out, via Twitter, that AstraZeneca's Charles Ferté, M.D., Ph.D., senior director and global project leader of oncology R&D, was leaving the Big Pharma, but we didn't know for where.
BioSpace
May 3, 2021
BioSpace
Ms. O'Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease
Alex Keown
April 16, 2021
BioSpace
In an effort to boost drug discovery for the "toughest drug discovery problems" through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.